October Podcast: Ebola, Biosimilars, Astellas, CLL
This article was originally published in The Pink Sheet Daily
Topics in the October “Pinkcast” include Ebola products, biosimilars marketing, Astellas in the U.S., and our market snapshot of chronic lymphocytic leukemia drugs.
You may also be interested in...
FDA expects few people would get the disease in the U.S., but many could receive a vaccine.
Astellas Pharma US expects oncology will account for 40% of sales in three years, becoming its top business segment – significant growth for a company that just four years ago had no commercial presence in oncology. The plans rely heavily on Xtandi, suggesting it might be time to ramp up business development activity.
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.